Purchase this article with an account.
O. Dembinska, K. Stout, J. Griffin, D. Rodeheaver, J. Heaton, R. Rice, J. Hiddemen; Preservation of the Retinal Function Following a Single Intravitreal Injection of VIGAMOX ® Solution in Non–Human Primates . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4681.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate retinal function by electroretinography after a single intravitreal application of VIGAMOX® solution in Cynomolgus monkeys.
In this study, either 60 µL of vehicle or 10, 20 or 60 µL of VIGAMOX® solution (50, 100 or 300 µg of moxifloxacin, respectively) was administered via a single intravitreal injection into the right eye of Cynomolgus monkeys (n=6 in each group). Retinal function was assessed with full–field electroretinograms at the baseline, 1 month and 2 months post–injection. Amplitudes and peak times of rod b–wave, mixed a–wave, mixed b–wave and cone b–wave were measured and statistically analyzed.
Eight weeks post–injection the a–waves analysis did not reveal any treatment–related significant differences in amplitudes and peak times between vehicle–injected and VIGAMOX–injected groups ([146.8±35.0 µV, 17.4±2.2 msec] vs. [183.0±27.0 µV, 15.6±0.5 msec] vs. [197.8±57.3 µV, 15.8±0.6 msec] vs. [184.7±38.5 µV, 15.2±0.7 msec]). Similarly, the analysis of rod ([163.5±53.0 µV, 72.7±4.3 msec] vs. [186.5±34.4 µV, 70.4±2.0 msec] vs. [219.3±40.8 µV, 74.3±9.0 msec] vs. [226.8±25.0 µV, 71.6±5.9 msec]), mixed ([299.5±63.1 µV, 40.5±5.7 msec] vs. [344.3±26.9 µV, 40.4±7.3 msec] vs. [363.2.8±80.7 µV, 47.4±3.2 msec] vs. [370±51.5 µV, 40.5±4.8 msec]) and cone ([122.8±23.7 µV, 30.4±0.9 msec] vs. [137.3±21.1 µV, 29.9±1.2 msec] vs. [126.7±13.8 µV, 30.8±1.1 msec] vs. [158.8±14.9 µV, 29.5±1.0 msec]) b–waves yielded no significant, treatment–related differences in amplitudes and peak times obtained from the four groups. Overall, some of the measurements for vehicle and treatment groups obtained at 8 weeks post–injection were slightly different from the values recorded at 4 weeks and at the baseline. Most probably, these results were non–treatment related consequence of the intravitreal intervention.
Retinal function was similar between vehicle and VIGAMOX® solution (0.5% moxifloxacin) treated eyes of Cynomolgus monkeys as assessed by the full–field electroretinogram following a single intravitreal injection.
This PDF is available to Subscribers Only